JP2010523117A - 体細胞の再プログラミング - Google Patents

体細胞の再プログラミング Download PDF

Info

Publication number
JP2010523117A
JP2010523117A JP2010502158A JP2010502158A JP2010523117A JP 2010523117 A JP2010523117 A JP 2010523117A JP 2010502158 A JP2010502158 A JP 2010502158A JP 2010502158 A JP2010502158 A JP 2010502158A JP 2010523117 A JP2010523117 A JP 2010523117A
Authority
JP
Japan
Prior art keywords
cells
cell
somatic
gene
reprogramming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010502158A
Other languages
English (en)
Japanese (ja)
Inventor
ルドルフ ジャニッシュ，
ジェイコブ ハンナ，
マリウス ウェルニク，
クリストファー ジェイ． レングナー，
アレクサンダー マイスナー，
オリバー トビアス ブラムブリンク，
ジー． グラント ウェルステッド，
ルース フォアマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of JP2010523117A publication Critical patent/JP2010523117A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0273—Cloned vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
JP2010502158A 2007-04-07 2008-04-07 体細胞の再プログラミング Withdrawn JP2010523117A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92212107P 2007-04-07 2007-04-07
US95934107P 2007-07-12 2007-07-12
US3606508P 2008-03-12 2008-03-12
PCT/US2008/004516 WO2008124133A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014251545A Division JP2015051022A (ja) 2007-04-07 2014-12-12 体細胞の再プログラミング

Publications (1)

Publication Number Publication Date
JP2010523117A true JP2010523117A (ja) 2010-07-15

Family

ID=39831277

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2010502158A Withdrawn JP2010523117A (ja) 2007-04-07 2008-04-07 体細胞の再プログラミング
JP2014251545A Withdrawn JP2015051022A (ja) 2007-04-07 2014-12-12 体細胞の再プログラミング
JP2016221842A Withdrawn JP2017035113A (ja) 2007-04-07 2016-11-14 体細胞の再プログラミング
JP2018027715A Withdrawn JP2018086017A (ja) 2007-04-07 2018-02-20 体細胞の再プログラミング
JP2019183744A Withdrawn JP2020014480A (ja) 2007-04-07 2019-10-04 体細胞の再プログラミング
JP2019183743A Active JP6934501B2 (ja) 2007-04-07 2019-10-04 体細胞の再プログラミング
JP2021204107A Pending JP2022031941A (ja) 2007-04-07 2021-12-16 体細胞の再プログラミング
JP2024000151A Pending JP2024024049A (ja) 2007-04-07 2024-01-04 体細胞の再プログラミング

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2014251545A Withdrawn JP2015051022A (ja) 2007-04-07 2014-12-12 体細胞の再プログラミング
JP2016221842A Withdrawn JP2017035113A (ja) 2007-04-07 2016-11-14 体細胞の再プログラミング
JP2018027715A Withdrawn JP2018086017A (ja) 2007-04-07 2018-02-20 体細胞の再プログラミング
JP2019183744A Withdrawn JP2020014480A (ja) 2007-04-07 2019-10-04 体細胞の再プログラミング
JP2019183743A Active JP6934501B2 (ja) 2007-04-07 2019-10-04 体細胞の再プログラミング
JP2021204107A Pending JP2022031941A (ja) 2007-04-07 2021-12-16 体細胞の再プログラミング
JP2024000151A Pending JP2024024049A (ja) 2007-04-07 2024-01-04 体細胞の再プログラミング

Country Status (9)

Country Link
US (5) US9382515B2 (cg-RX-API-DMAC7.html)
EP (3) EP2145000A4 (cg-RX-API-DMAC7.html)
JP (8) JP2010523117A (cg-RX-API-DMAC7.html)
CN (2) CN105861443A (cg-RX-API-DMAC7.html)
AU (1) AU2008236629B2 (cg-RX-API-DMAC7.html)
CA (2) CA3071055A1 (cg-RX-API-DMAC7.html)
MX (2) MX352541B (cg-RX-API-DMAC7.html)
RU (1) RU2502799C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008124133A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012115270A1 (ja) * 2011-02-25 2012-08-30 学校法人慶應義塾 ｉＰＳ細胞クローンの選択方法、及びその選択方法に用いる遺伝子の選択方法

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
WO2007053184A2 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
JP4395193B2 (ja) 2005-08-01 2010-01-06 ニューポテンシャル，インコーポレイテッド 回復能を有する再プログラムされた細胞の作製
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
MX352541B (es) 2007-04-07 2017-11-29 Whitehead Inst Biomedical Res Reprogramación de células somáticas.
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
WO2009032194A1 (en) * 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
EP2227241A1 (en) * 2007-11-30 2010-09-15 Cytomatrix PTY LTD Methods of inducing pluripotency involving sox2 protein
WO2009067757A1 (en) * 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving oct4 protein
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
JP5626619B2 (ja) * 2008-12-08 2014-11-19 国立大学法人京都大学 効率的な核初期化方法
AU2008286249B2 (en) 2007-12-10 2013-10-10 Kyoto University Efficient method for nuclear reprogramming
AU2009233845A1 (en) * 2008-04-07 2009-10-15 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator
SG10201400329YA (en) 2008-05-02 2014-05-29 Univ Kyoto Method of nuclear reprogramming
CA2969377C (en) 2008-06-13 2019-12-03 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
KR101642790B1 (ko) * 2008-07-07 2016-07-27 다카라 바이오 가부시키가이샤 다능성 줄기세포의 제조방법
WO2010027062A1 (ja) * 2008-09-04 2010-03-11 独立行政法人理化学研究所 B細胞由来iPS細胞およびその用途
US20100062534A1 (en) * 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
WO2010056808A2 (en) * 2008-11-12 2010-05-20 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
WO2010075330A1 (en) 2008-12-23 2010-07-01 Segetis, Inc. Ketal amide compounds, methods of making, and applications
EP2401372A4 (en) * 2009-02-27 2012-09-19 Univ Kyoto NEW NUCLEAR REPROGRAMMING SUBSTANCE
US9487756B2 (en) * 2009-03-20 2016-11-08 Mesoblast, Inc. Production of reprogrammed pluripotent cells
CN101580816B (zh) * 2009-04-23 2012-02-29 中国科学院广州生物医药与健康研究院 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法
EP2421956A4 (en) * 2009-04-24 2013-10-02 Whitehead Biomedical Inst COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS
JP5886195B2 (ja) 2009-07-09 2016-03-16 ホワイトヘッド・インスティチュート・フォア・バイオメディカル・リサーチ 哺乳動物遺伝学のための組成物および方法、ならびにその使用
JP5709015B2 (ja) 2009-08-19 2015-04-30 国立大学法人大阪大学 角膜移植用シート
EP2470664A4 (en) 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
US9340772B2 (en) 2009-10-29 2016-05-17 Mcmaster University Generating induced pluripotent stem cells and progenitor cells from fibroblasts
US9696297B2 (en) * 2009-12-23 2017-07-04 Salk Institute For Biological Studies Method for preparing an X chromosome inactivated female human neural cell
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9089520B2 (en) * 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
JP2013545439A (ja) 2010-09-17 2013-12-26 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 多能性幹細胞の有用性および安全性の特徴決定を行うための機能的ゲノミクスアッセイ
JP5888753B2 (ja) 2010-11-04 2016-03-22 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
EP2647699B1 (en) 2010-12-03 2020-04-01 Kyoto University Efficient method for establishing induced pluripotent stem cells
CN102731653B (zh) * 2011-04-06 2013-12-11 李凌松 一种抗磷酸化Oct4蛋白的抗体及其应用
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
CA2858148C (en) 2011-12-05 2023-03-14 Factor Bioscience Inc. Methods and products for transfecting cells
US20130202649A1 (en) * 2012-01-17 2013-08-08 The Board Of Trustees Of The Leland Stanford Junior University Activation of innate immunity for nuclear reprogramming of somatic cells
CA2885576A1 (en) 2012-04-24 2013-10-31 The Brigham And Women's Hospital, Inc. Generating pluripotent cells de novo
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014057997A1 (ja) 2012-10-09 2014-04-17 Hayashi Nakanobu 初期化ペプチド及びその用途
US20140287932A1 (en) 2012-10-25 2014-09-25 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9857360B2 (en) 2013-01-25 2018-01-02 Xcell Biosciences, Inc. Cancer analysis system
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
JP6456350B2 (ja) * 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
JP7182852B2 (ja) 2013-03-15 2022-12-05 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 神経変性疾患のための細胞性発見プラットフォーム
JP2016521971A (ja) 2013-04-23 2016-07-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 単離ナイーブ型多能性幹細胞およびそれを発生させる方法関連出願本出願は、米国特許法１１９条第（ｅ）項に基づき、２０１４年１月２９日出願の米国特許仮出願第６１／９３２，９３５号、２０１３年９月１７日出願の米国特許仮出願第６１／８７８，７６９号、および２０１３年４月２３日出願の米国特許仮出願第６１／８１４，９２０号の優先権を主張する。また、本出願は、同時に提出された同出願人による同時係属出願である、ＹａｑｕｂＨＡＮＮＡ、ＮｏａＮＯＶＥＲＳＨＴＥＲＮ、およびＹｏａｃｈＲＡＩＳによる米国特許出願（発明の名称「単離ナイーブ型多能性幹細胞およびそれを発生させる方法（ＩＳＯＬＡＴＥＤＮＡＩＶＥＰＬＵＲＩＰＯＴＥＮＴＳＴＥＭＣＥＬＬＳＡＮＤＭＥＴＨＯＤＳＯＦＧＥＮＥＲＡＴＩＮＧＳＡＭＥ）」）（代理人事件記録簿第５８８７０号）にも関する。上記出願の内容はその全体を参考として本明細書に組み込む。
JP6467406B2 (ja) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
JP6697380B2 (ja) 2013-06-10 2020-05-20 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 多能性幹細胞の有用性および安全性を特徴付けるための初期発生ゲノムアッセイ
EP3045531B1 (en) 2013-09-12 2023-08-30 Kaneka Corporation Method for inducing differentiation of induced pluripotent stem cells and method for selecting induced pluripotent stem cells
US11767507B2 (en) 2013-11-08 2023-09-26 The Mclean Hospital Corporation Methods for efficient generation of GABAergic interneurons from pluripotent stem cells
RU2714404C2 (ru) 2014-01-31 2020-02-14 Фэктор Байосайенс Инк. Способы и продукты для получения и доставки нуклеиновых кислот
EP3991751A1 (en) 2014-02-10 2022-05-04 The Board of Trustees of the Leland Stanford Junior University Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mrna
MX391776B (es) 2014-03-19 2025-03-11 Vcell Therapeutics Inc Métodos relacionados con células pluripotentes.
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
EP3842514A1 (en) 2014-09-12 2021-06-30 Whitehead Institute for Biomedical Research Cells expressing apolipoprotein e and uses thereof
EP3200808B1 (en) 2014-10-03 2024-07-31 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN112481211B (zh) 2015-01-26 2024-07-05 儿童医院公司 免疫调节性提高的细胞及其使用和生产方法
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2016164463A1 (en) 2015-04-07 2016-10-13 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
EP3708680B8 (en) 2015-04-15 2023-08-30 University of Massachusetts Compositions and methods for xi chromosome reactivation
US20170044609A1 (en) * 2015-04-24 2017-02-16 California Institute Of Technology Reactivation of x chromosome genes
WO2016172734A1 (en) 2015-04-24 2016-10-27 California Institute Of Technology Reactivation of x chromosome genes
JP2018520688A (ja) 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
US10662409B2 (en) * 2015-09-09 2020-05-26 Trustees Of Tufts College Methods of generating neural stem cells
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN105624117A (zh) * 2016-01-18 2016-06-01 哈尔滨医科大学 一种低氧促进小鼠成纤维细胞重编程为心肌细胞的方法
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US20170369904A1 (en) * 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
CN116115629A (zh) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 核酸产品及其施用方法
AU2017313912B2 (en) 2016-08-19 2024-01-04 Whitehead Institute For Biomedical Research Methods of editing DNA methylation
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
CN106544315A (zh) * 2016-10-12 2017-03-29 广东艾时代生物科技有限责任公司 一种脂肪间充质干细胞诱导成多能干细胞的方法
WO2018081661A1 (en) 2016-10-27 2018-05-03 California Institute Of Technology Hdac inhibitor compositions for reactivation of the x chromosome
EP4461323A3 (en) 2016-12-16 2025-01-15 Iviva Medical, Inc. Thin film interposition for basement membrane scaffolds
US11873496B2 (en) 2017-01-09 2024-01-16 Whitehead Institute For Biomedical Research Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
WO2018159805A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 膵前駆細胞の製造方法
CN110088272B (zh) * 2017-04-05 2023-08-04 阿斯加德治疗有限公司 用于将细胞重编程为树突状细胞或抗原呈递细胞的组合物、其方法和用途
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US20200208093A1 (en) 2017-06-14 2020-07-02 Takeda Pharmaceutical Company Limited Cell-sealing device
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
PL241125B1 (pl) 2017-11-30 2022-08-08 Gdanski Univ Medyczny Kompozycja farmaceutyczna do zastosowania jako środek do pobudzania regeneracji lub gojenia ran
SG11202004964WA (en) 2017-11-30 2020-06-29 Univ Kyoto Method for culture of cells
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE
TWI821230B (zh) 2017-12-22 2023-11-11 日商千紙鶴治療公司 細胞培養裝置、培養液吸引器及細胞培養方法
CN108624621B (zh) * 2018-01-17 2019-04-12 中国科学院上海生命科学研究院 非人灵长类的体细胞克隆动物的制备方法
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
US20210060210A1 (en) 2018-03-19 2021-03-04 Kyoto University Hydrogel capsule
CN111918961B (zh) 2018-03-30 2023-10-24 国立大学法人京都大学 心肌细胞成熟促进剂
JP7440868B2 (ja) 2018-03-30 2024-02-29 国立大学法人京都大学 細胞の製造方法
EP3778587B1 (en) 2018-03-30 2023-10-04 Orizuru Therapeutics, Inc. Heterocyclic compound
KR102848466B1 (ko) 2018-04-23 2025-08-20 오리즈루 세라퓨틱스 가부시키가이샤 증식 억제제
CN112912490B (zh) 2018-08-03 2023-12-26 千纸鹤治疗公司 细胞制造方法
CN112567025B (zh) 2018-08-10 2025-01-17 国立大学法人京都大学 Cd3阳性细胞的制造方法
JP7436990B2 (ja) 2018-08-10 2024-02-22 国立大学法人京都大学 カチオン性脂質を用いた心筋細胞へのトランスフェクション方法
KR20210049779A (ko) 2018-08-22 2021-05-06 고쿠리츠 다이가쿠 호진 교토 다이가쿠 장관 신경전구세포의 제조 방법
SG11202101930XA (en) 2018-08-31 2021-03-30 Noile Immune Biotech Inc Car-expressing t cells and car expression vector
SG11202102748WA (en) 2018-09-19 2021-04-29 Takeda Pharmaceuticals Co Insulin-producing cells
US12097239B2 (en) 2018-09-21 2024-09-24 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching MRNA coding for secreted proteins
WO2020080270A1 (ja) 2018-10-15 2020-04-23 公立大学法人横浜市立大学 栄養組成物
KR20210109000A (ko) 2018-12-27 2021-09-03 고쿠리츠 다이가쿠 호진 교토 다이가쿠 T-세포 수용체 개변체
WO2020150391A1 (en) * 2019-01-15 2020-07-23 Falcon Therapeutics, Inc. Engineered stem cell constructs and uses thereof
EP3919124A4 (en) 2019-02-01 2022-11-23 Kyoto University CELL DETECTION METHOD
JP7533896B2 (ja) 2019-03-29 2024-08-14 公立大学法人横浜市立大学 スクリーニング方法および毒性評価法
BR112021020115A2 (pt) 2019-04-10 2021-12-07 Orizuru Therapeutics Inc Composição, estrutura semelhante a tecido biológico, e, método para produzir uma estrutura semelhante a tecido biológico
BR112021022432A2 (pt) 2019-05-14 2021-12-28 Aleph Farms Ltd Agregados de células pluripotentes e uso dos mesmos
EP3985104A4 (en) 2019-06-11 2023-04-12 Kyoto University PROCEDURE FOR GENERATING A KIDNEY INTERSTITIAL CELL
CN119569589A (zh) 2019-07-03 2025-03-07 菲克特生物科学股份有限公司 阳离子脂质及其用途
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
JP7541748B2 (ja) 2019-08-20 2024-08-29 オリヅルセラピューティクス株式会社 心筋細胞の富化方法
WO2021079874A1 (ja) 2019-10-21 2021-04-29 武田薬品工業株式会社 増殖抑制剤
WO2021085576A1 (ja) 2019-11-01 2021-05-06 国立大学法人京都大学 Ｔ細胞の製造方法
EP4067490A4 (en) 2019-11-25 2024-02-21 Kyoto University T-cell master cell bank
EP4123015A4 (en) 2020-03-19 2024-05-22 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
WO2021187602A1 (ja) 2020-03-19 2021-09-23 国立大学法人京都大学 心筋細胞の精製方法
EP4130253A4 (en) 2020-03-31 2024-05-29 Kyoto University METHOD FOR PRODUCING T-LYMPHOCYTE PROGENITORS
EP4159838A4 (en) 2020-05-28 2024-07-17 Orizuru Therapeutics, Inc. MASS PRODUCTION PROCESS OF UNIFORM SIZED CELL AGGREGATES
CN112201307B (zh) * 2020-09-23 2024-09-17 温州医科大学 一种转录本注释方法以及筛选长非编码rna和内源逆转录病毒来源长非编码rna的方法
EP4249587A4 (en) 2020-11-20 2025-02-19 Orizuru Therapeutics, Inc. RIPENING AGENT
JPWO2022172960A1 (cg-RX-API-DMAC7.html) 2021-02-09 2022-08-18
CN116964193A (zh) 2021-03-09 2023-10-27 国立大学法人东京医科齿科大学 细胞簇的制造方法
CN117136231A (zh) 2021-04-08 2023-11-28 武田药品工业株式会社 用于激活t细胞的方法
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
WO2022230919A1 (ja) 2021-04-28 2022-11-03 国立大学法人 東京医科歯科大学 細胞の製造方法
CN113278686A (zh) * 2021-06-11 2021-08-20 扬州大学 一种研究dna甲基化调控重编程过程的方法
MX2024003619A (es) 2021-09-27 2024-04-19 Univ Kyoto Metodo para producir celulas t.
WO2023149555A1 (ja) 2022-02-04 2023-08-10 国立大学法人京都大学 Ｔ細胞の製造方法
JPWO2023182328A1 (cg-RX-API-DMAC7.html) 2022-03-23 2023-09-28
WO2023210578A1 (ja) 2022-04-25 2023-11-02 オリヅルセラピューティクス株式会社 Ａｌｋ５阻害活性とｃｄｋ８／１９阻害活性とを有する成熟化剤
EP4541882A4 (en) 2022-06-17 2025-10-15 Univ Kyoto METHOD FOR PRODUCING THYMIC EPITHELIAL CELLS
EP4556555A1 (en) 2022-07-14 2025-05-21 Orizuru Therapeutics, Inc. Fibrin gel sheet for cell transplantation
CN119698464A (zh) 2022-07-25 2025-03-25 国立大学法人京都大学 从灵长类的胚胎卵巢细胞诱导卵泡的体外培养法
WO2024024551A1 (ja) 2022-07-26 2024-02-01 国立大学法人京都大学 シェディング構造を有する人工受容体
JPWO2024029617A1 (cg-RX-API-DMAC7.html) 2022-08-05 2024-02-08
EP4570902A1 (en) 2022-08-08 2025-06-18 Healios K.K. Method for producing cell aggregates
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells
EP4596675A1 (en) 2022-09-26 2025-08-06 Kyoto University Method for producing pancreatic endoderm cells
TW202421780A (zh) 2022-09-26 2024-06-01 國立大學法人京都大學 T細胞的製造方法
JPWO2024071280A1 (cg-RX-API-DMAC7.html) 2022-09-29 2024-04-04
WO2024106444A1 (ja) 2022-11-16 2024-05-23 学校法人関西医科大学 着床促進薬とそのスクリーニング系
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025106897A1 (en) * 2023-11-16 2025-05-22 Colossal Biosciences Inc. Methods and compositions for creating induced pluripotent stem cells
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JP2002529070A (ja) * 1998-11-09 2002-09-10 モナシュ・ユニヴァーシティ 胚性幹細胞
WO2005080598A1 (ja) * 2004-02-19 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 体細胞核初期化物質のスクリーニング方法
WO2005090557A1 (ja) * 2004-03-23 2005-09-29 Daiichi Asubio Pharma Co., Ltd. 多能性幹細胞の増殖方法
WO2007069666A1 (ja) * 2005-12-13 2007-06-21 Kyoto University 核初期化因子
WO2008118820A2 (en) * 2007-03-23 2008-10-02 Wisconsin Alumni Research Foundation Somatic cell reprogramming

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US4846835A (en) 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5824837A (en) * 1993-07-22 1998-10-20 Merck & Co., Inc. Expression of human interleukin-1β in a transgenic animal
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5698446A (en) 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
GB9517779D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9809178D0 (en) * 1998-04-29 1998-07-01 Univ Edinburgh Nuclear reprogramming of somatic cells
EP1147176B1 (en) * 1999-02-04 2009-12-16 Pluristem Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
AU2002242173A1 (en) 2001-02-15 2002-08-28 Whithead Institute For Biomedical Research Stem cell identification
US20020137460A1 (en) * 2001-03-08 2002-09-26 Howard Sun Universal multi-band (5 bands and more) keyless RF remote control unit using bluetooth radio module as the base
US7250255B2 (en) 2001-05-31 2007-07-31 Shinya Yamanaka Genes with ES cell-specific expression
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
JPWO2003027277A1 (ja) 2001-09-21 2005-01-06 独立行政法人 科学技術振興機構 再プログラム化因子のスクリーニング方法、該方法によりスクリーニングされた再プログラム化因子および該再プログラム化因子を利用する方法、並びに、未分化融合細胞を分化させる方法および細胞、組織、臓器の製造方法
DE10162080A1 (de) * 2001-12-10 2003-06-26 Albrecht Mueller Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential
GB0202149D0 (en) * 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0211904D0 (en) * 2002-05-23 2002-07-03 Medical Res Council Nuclear transfer
WO2004009758A2 (en) 2002-07-23 2004-01-29 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
PL1641916T3 (pl) * 2003-06-27 2016-08-31 Depuy Synthes Products Inc Regeneracja i naprawa tkanki nerwowej z wykorzystaniem komórek poporodowych
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
EP1574499A1 (en) 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
US20060148104A1 (en) 2004-10-29 2006-07-06 Massachusetts Institute Of Technology Detection of ion channel or receptor activity
KR20080036549A (ko) * 2005-04-29 2008-04-28 이노베이티브 데어리 프로덕츠 피티와이 리미티드 애즈 트러스티 포 더 파티시펀츠 오브 더 코오퍼레이티브 리서치 센터 포 이노베이티브 데어리 프로덕츠 포유류 배아 유래의 줄기 세포 또는 줄기 세포 유사 세포의제조 방법
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
JP4395193B2 (ja) * 2005-08-01 2010-01-06 ニューポテンシャル，インコーポレイテッド 回復能を有する再プログラムされた細胞の作製
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
JP2009542626A (ja) 2006-06-27 2009-12-03 ジャワハーラル ネール センター フォー アドヴァンスド サイエンティフィック リサーチ メチルトランスフェラーゼ（ｈｍｔａｓｅ）の部位特異的阻害剤及びその製剤方法
MX352541B (es) 2007-04-07 2017-11-29 Whitehead Inst Biomedical Res Reprogramación de células somáticas.
WO2009032456A2 (en) * 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009032194A1 (en) * 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
US20110061118A1 (en) 2008-03-17 2011-03-10 Helmholtz Zentrum Munchen Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
CA2718904C (en) 2008-03-17 2017-01-03 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
SG10201400329YA (en) 2008-05-02 2014-05-29 Univ Kyoto Method of nuclear reprogramming
CA2969377C (en) * 2008-06-13 2019-12-03 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
WO2010033920A2 (en) 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
US20100150889A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic Vector For Human Induced Pluripotent Stem Cell Production

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JP2002529070A (ja) * 1998-11-09 2002-09-10 モナシュ・ユニヴァーシティ 胚性幹細胞
WO2005080598A1 (ja) * 2004-02-19 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 体細胞核初期化物質のスクリーニング方法
WO2005090557A1 (ja) * 2004-03-23 2005-09-29 Daiichi Asubio Pharma Co., Ltd. 多能性幹細胞の増殖方法
WO2007069666A1 (ja) * 2005-12-13 2007-06-21 Kyoto University 核初期化因子
WO2008118820A2 (en) * 2007-03-23 2008-10-02 Wisconsin Alumni Research Foundation Somatic cell reprogramming

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COWAN,C.A. ET AL.: "Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells.", SCIENCE, vol. 309, no. 5739, JPN6013018562, 26 August 2005 (2005-08-26), pages 1369 - 73, XP002425303, ISSN: 0002548307, DOI: 10.1126/science.1116447 *
NATURE, vol. 441, JPN6014034277, 2006, pages 997 - 1001, ISSN: 0002876578 *
STRELCHENKO, N. ET AL.: "Reprogramming of human somatic cells by embryonic stem cell cytoplast.", REPROD. BIOMED. ONLINE, vol. 12, no. 1, JPN6013018572, January 2006 (2006-01-01), pages 107 - 11, XP027045634, ISSN: 0002548306 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012115270A1 (ja) * 2011-02-25 2012-08-30 学校法人慶應義塾 ｉＰＳ細胞クローンの選択方法、及びその選択方法に用いる遺伝子の選択方法
JPWO2012115270A1 (ja) * 2011-02-25 2014-07-07 学校法人慶應義塾 ｉＰＳ細胞クローンの選択方法、及びその選択方法に用いる遺伝子の選択方法

Also Published As

Publication number Publication date
JP2018086017A (ja) 2018-06-07
EP2626416A2 (en) 2013-08-14
EP3878949A1 (en) 2021-09-15
JP2022031941A (ja) 2022-02-22
US9382515B2 (en) 2016-07-05
JP6934501B2 (ja) 2021-09-15
RU2009140903A (ru) 2011-05-20
MX352541B (es) 2017-11-29
JP2024024049A (ja) 2024-02-21
JP2020014480A (ja) 2020-01-30
WO2008124133A1 (en) 2008-10-16
CN105861443A (zh) 2016-08-17
JP2020014479A (ja) 2020-01-30
US20250188423A1 (en) 2025-06-12
JP2015051022A (ja) 2015-03-19
CA3071055A1 (en) 2008-10-16
AU2008236629A1 (en) 2008-10-16
US9714414B2 (en) 2017-07-25
JP2017035113A (ja) 2017-02-16
MX2009010847A (es) 2010-04-27
EP2145000A4 (en) 2010-05-05
MX348010B (es) 2017-05-23
EP2145000A1 (en) 2010-01-20
CA2683056A1 (en) 2008-10-16
US10093904B2 (en) 2018-10-09
AU2008236629B2 (en) 2014-03-06
CA2683056C (en) 2020-03-24
CN101932705A (zh) 2010-12-29
US20150118755A1 (en) 2015-04-30
US20190241874A1 (en) 2019-08-08
RU2502799C2 (ru) 2013-12-27
US20110076678A1 (en) 2011-03-31
US20170342386A1 (en) 2017-11-30
EP3878949B1 (en) 2025-06-04
EP2626416A3 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
JP6934501B2 (ja) 体細胞の再プログラミング
US20170211048A1 (en) Enhanced reprogramming to ips cells
US20170088820A1 (en) GENERATION OF INDUCED PLURIPOTENT STEM (iPS) CELLS
JP2010528622A (ja) 体細胞から多能性細胞を生成する方法
AU2024203525A1 (en) Reprogramming of somatic cells
WO2014096800A1 (en) Novel method
AU2020213357B2 (en) Reprogramming of somatic cells
US20130102479A1 (en) Methods of enhancing pluripotentcy
HK40058787A (en) Reprogramming of somatic cells
HK1227936A1 (en) Reprogramming of somatic cells

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130828

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141212

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141225

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150306

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160909